Cipla gains 1%; launches Hepatitis C drug

India Infoline News Service | Mumbai | December 21, 2015 11:41 IST

The pharmaceutical company launched Generic Ledipasvir and Sofosbuvir to treat Hepatitis C, as per media reports.

Cipla
Shares of Cipla were trading higher by 1% at Rs.646.65 after the pharmaceutical company launching Generic Ledipasvir and Sofosbuvir to treat Hepatitis C, as per media reports.

The scrip opened at Rs. 643.15 and has touched a high and low of Rs. 647.95 and Rs. 640.8 respectively. So far 234676(NSE+BSE) shares were traded on the counter. The current market cap of the company is Rs. 51575.91 crore.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 752.45 on 10-Mar-2015 and a 52 week low of Rs. 572 on 15-Jun-2015. Last one week high and low of the scrip stood at Rs. 648.75 and Rs. 632 respectively.

The promoters holding in the company stood at 36.79 % while Institutions and Non-Institutions held 34.24 % and 26.63 % respectively.

The stock is currently trading above its 200 DMA.

***Note: This is a NSE Chart

 

Advertisements

  • Save upto Rs.2.67 lakh with Pradhan Mantri Awas Yojana ...Know more
  • Now Save Rs.3150 on your Demat Account ...Click here
  • Now get IIFL Personal Loan in just 8* hours...APPLY NOW!
  • Get the most detailed result analysis on the web - Real Fast!
  • Actionable & Award-Winning Research on 500 Listed Indian Companies.